Skip to content

The Efficacy of Citalopram Treatment in Acute Stroke

The Efficacy of Citalopram Treatment in Acute Stroke

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01937182
Acronym
TALOS
Enrollment
642
Registered
2013-09-09
Start date
2013-09-30
Completion date
2016-12-19
Last updated
2017-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Ischemic

Keywords

Stroke, SSRI (Selective Serotonin Reuptake Inhibitors), Serotonin, 5-HT (5-Hydroxytryptamine), Neuroprotection, MRI (Magnetic Resonance Imaging), Platelet, CT (computerized tomography), Post Stroke Depression

Brief summary

We wish to conduct a prospective, randomized, double blind, placebo controlled multi center study of the combined neuroprotective and antithrombotic effects of SSRI treatment after stroke. Hypotheses: SSRI treatment commenced in the acute phase of stroke (day 0-7) protects against new thromboembolic events and leads to better rehabilitation. 600 stroke patients will be randomized in a 1:1 ratio. The treatment and follow up period is 6 months. During these 6 months there will be 2 clinical follow up visits, one telephone control and one visit to evaluate compliance regarding medication.

Detailed description

Design TALOS is an investigator-initiated, national multicenter randomized- and placebo-controlled, double blind trial testing citalopram in acute ischemic stroke. Randomization Eligible patients will be randomized 1:1 to treatment with either citalopram or placebo. Treatment allocation is double-blinded based on computer-generated algorithm via a dedicated website. Patients whose treatment is stopped within 31 days after inclusion will be replaced. Intervention and follow-up Patients randomized to citalopram will receive oral treatment with 20 mg tablets (10 mg if age ≥65 and/or reduced liver function) for 6 months with telephone contact after 2 weeks and 3 months and follow-up visits at 1 and 6 months. If patients develop depression dosage is initially doubled, followed by an additional control to evaluate effect and, if necessary, shifted to open-label antidepressant treatment. After 6 months, treatment will either stop or switch to open-label antidepressants at the discretion of the investigator. Substudy 120 of patients will begin treatment within 12 hours after treatment with recombinant tissue plasminogen activator. These patients will receive a standard acute magnetic resonance imaging (MRI) with additional perfusion and angio sequences. The 24-hour control scan will be done using MRI instead of conventional CT. Data monitoring When 300 patients have been included in the trial, an interim analysis will be performed. The unblinded results of this analysis will be reviewed by an independent data monitoring committee.

Interventions

DRUGCitalopram

Citalopram 10-40 mg per day administered orally

DRUGPlacebo

1/2-2 tablets per day with no intrinsic drug activity

Sponsors

Danish Council for Independent Research
CollaboratorOTHER
The Danish Regions Medicine Foundation
CollaboratorUNKNOWN
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* First ever ischemic stroke * Age 18 years or above

Exclusion criteria

* Hemorrhagic stroke * Dementia or other neurodegenerative disease * Antidepressant medical treatment within 6 months of admission * Acute need for antidepressant treatment * Drug abuse or other conditions that may indicate noncompliant behavior * Liver failure (increased liver enzyme levels up to or more than 2 times upper limit) * Renal failure (eGFR below 30 ml/min per 1.73m2) * Hyponatremia (S-potassium below 130 mmol/l) * Actively bleeding ulcer * Fatal stroke or other severe co-morbidity that markedly decreases expected life span * Prolonged corrected QT-interval (QTc above 480 ms) * Ongoing treatment with drugs known to prolong the QTc interval

Design outcomes

Primary

MeasureTime frameDescription
Vascular death, Transient Ischemic Attack (TIA)/stroke and myocardial infarction (combined)6 monthsMyocardial Infarction: STEMI (ST segment elevation myocardial infarction) and NSTEMI (non-ST segment elevation myocardial infarction)
Functional status at 6-months6 monthsFunctional status at 6-months, measured by the modified Rankin Scale

Secondary

MeasureTime frameDescription
Death of any cause6 months
TIA/stroke6 months
Bleeding6 monthsUsing the Global Utilization Of Streptokinase And Tpa For Occluded Arteries definition for bleeding (GUSTO)
Myocardial infarction6 monthsSTEMI (ST segment elevation myocardial infarction) and NSTEMI (non-ST segment elevation myocardial infarction)
Disability/dependence6 monthsUsing the modified Rankin Scale and the Barthel Index (BI)
Lesion size6 monthsUsing FLAIR positive lesion size on MRI 24 hours after treatment with Alteplase
Cognitive and organic cerebral impairment6 monthsUsing the Mini-Mental State Examination and the Symbol Digit Modalities Test
Fatigue6 monthsUsing the Multidimensional Fatigue Inventory
Post-stroke depression6 monthsUsing the Major Depression Inventory test (MDI), Global depression scale (self and clinician and Hamilton Depression Scale - 6 item (HAM-D6)
Pathological Crying6 monthsUsing the Pathological Crying Scale
Physical activity6 monthsUsing the Physical Activity Scale for the Elderly (PASE)
Vascular death6 months

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026